Skip to main content

Clifford Chance

Clifford Chance

Regulatory Investigations and Financial Crime Insights

Spotlight on the EU Whistleblower Directive and Pharma and Healthcare sectors

There are several factors at play for companies in the pharma and healthcare sectors, which, when combined with the availability of rewards for whistleblowers under several US laws, as well as the EU's forthcoming whistleblowing regime, create an environment that is ripe for whistleblowing.

While the EU has traditionally been more resistant to the culture of whistleblowing, that is about to change with the union's new Whistleblower Protection Directive ("EU Directive"), which Member States must implement by December 17, 2021. Specifically, Member States are required to adopt laws aimed at making whistleblowing more accessible and protecting those who blow the whistle from retaliation. All private companies with more than 50 employees, no matter the sector, will be subject to the requirements of the EU Directive, as well as any additional requirements that the Member States in which they operate decide to impose.

Read our full briefing on the topic here.

  • Share on Twitter
  • Share on LinkedIn
  • Share via email
Back to top